Adagrasib,Cetuximab,Afatinib,Pembrolizumab
Mirati,Eli Lilly,Boehringer Ingelheim,Merck
['colorectal', 'agent', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'adagrasib', 'rectal', 'crcsm']
#esmo22 re: update of kras g12c adagrasib single-agent update with 1 yr os = 69% but combo with egfr inhibitor with rr = 46% and dcr but 1-yr = 61%. #crcsm #colorectal #cancer #clinicaltrials #cancerresearch 
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations